Biomineralized OMV-based nanocomposite orchestrates cascade-amplified antitumor immunity via eliciting dual

Yi Wang1,2, Ying Luo1, Wenli Zhang1

  • 1Department of Radiology, Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, P.R. China.

PubMed

Insights

This study introduces a novel nanocomposite that triggers dual pyroptosis and lysosomal cell death to overcome tumor resistance. This approach enhances immune response and enables real-time tumor imaging for effective cancer therapy.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Immunotherapy

Background:

  • Tumor resistance to apoptosis, immunosuppressive microenvironments, and adaptive survival mechanisms limit current cancer therapies.
  • Effective antitumor strategies require inducing potent tumor cell death and overcoming immune evasion.

Purpose of the Study:

  • To develop a multifunctional theranostic nanoplatform for activating pyroptosis and lysosomal cell death.
  • To overcome tumor resistance and enhance immunogenic cell death for immune-silent solid tumors.

Main Methods:

  • A biomineralized bacterial outer membrane vesicle-based nanocomposite (Gd-ZIF@OMV@DC661) was designed.
  • The nanocomposite was engineered to release Zn²⁺, Gd³⁺, and an autophagy inhibitor (DC661) upon acid-responsive degradation within tumor cells.
  • Activation of pyroptosis pathways and lysosomal cell death induction were analyzed, alongside immune response stimulation and MRI tracking.

Main Results:

  • The nanocomposite successfully induced dual pyroptosis (canonical and non-canonical) and lysosomal cell death via lipid peroxidation.
  • Inhibition of tumor autophagy by DC661 amplified pyroptosis and induced immunogenic cell death, releasing DAMPs and TAAs.
  • The nanoplatform facilitated DC maturation and T-cell activation, demonstrating a potent adaptive immune response and enabling T1-weighted MRI tumor tracking.

Conclusions:

  • The Gd-ZIF@OMV@DC661 nanoplatform offers a promising theranostic strategy for treating immune-silent solid tumors.
  • This approach effectively combines pyroptosis, lysosomal cell death, and immune activation for enhanced antitumor efficacy.
  • The theranostic capabilities allow for integrated treatment and real-time monitoring of tumor progression.

Related Concept Videos